Resources about TB
and TB Vaccine R&D

  • WHO Preferred Product Characteristics for New Tuberculosis Vaccine presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy.
  • TB Vaccine Development Pathway, developed by IAVI and TBVI, is an online tool that provides a structured development path and gating criteria for TB vaccine candidates. It includes considerations for target populations,  vaccine platforms, and market, access and implementation, as well as guidance for  planning and operating community engagement activities.
  • Tuberculosis Vaccines for Adults and Adolescents: Progress, Prospect, and Perspectives is a webinar organized by the Global Vaccine and Immunization Research Forum (GVIRF) that brought together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines through the status and strategies for product development, to the considerations for approval, policy recommendation and use. Video in EnglishVideo in SpanishVideo in FrenchPresentations
  • Directory of TB Vaccine Clinical Trial Sites in Sub-Saharan Africa, provided by EDCTP,  provides a comprehensive overview of trial sites and their capacity to conduct studies of TB vaccines in sub-Saharan Africa.
  • BCG World Atlas is an interactive map that provides detailed information on current and past BCG vaccination policies and practices for over 180 countries.

Contact us if you have resources about TB and TB vaccines that you would like to share.

Resources for Advocacy, Policy, and Funding

  • End TB Strategy from the World Health Organization’s Global TB Programme provides a 20-year strategy toward the goal of ending the TB epidemic, including research, development, and implementation of new tools.
  • Global Plan to End TB 2023-2030, published by the Stop TB Partnership, is a costed plan and roadmap for a concerted response to tuberculosis (TB) aligned with the WHO End TB Strategy, including a strategic framework for TB vaccine R&D.
  • Report on Tuberculosis Research Funding Trends, published annually by TAG, tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects.
  • An investment case for new TB vaccines summarizes the results of a full value proposition for new tuberculosis (TB) vaccines commissioned by WHO to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. A Q&A on how this work can be best used for TB vaccine advocacy is available here.
  • Investment Toolbox to Advance TB Vaccine Development through Joint Action is a policy brief co-authored by the TB Vaccine Advocacy Roadmap (TB Vax ARM) that outlines recommendations for G20 members to act together to accelerate TB vaccine development. The proposed "investment toolbox' is adaptable to each country's economic and research capacities and disease burden.
  • New TB vaccines needed to tackle AMR, published by TB Vax ARM, shares a collective call to decision-makers to prioritize TB vaccine R&D as a signature piece of global health and antimicrobial resistance (AMR) agendas. The brief, from the TB Vax ARM, draws on the latest research in health and economic modelling to demonstrate how new TB vaccines could significantly help control drug-resistant TB, in a cost-effective and affordable way.
  • Accountability to End Tuberculosis: A Global Responsibilitypublished by RESULTS UK, looks ahead to the UNHLM in September 2023 and makes the case for accountability within the global TB response, highlighting the lack of progress against the 2018 global commitments and the role of accountability within these commitments.
  • The Urgent Need for New TB Vaccines, published by TB Vax ARM, provides information and talking points about the importance of TB vaccines to meeting global targets to end TB and the need to invest in TB vaccine research and development.
  • Words Matter, published by Stop TB Partnership, is a communications tool for partners, stakeholders, and anyone affected or working in TB. The guide is a key instrument to encourage positive change, sensitize, promote appropriate language, end the stigmatization, and empower people affected by TB.
  • Modeling in TB vaccine development provides an overview of mathematical modeling for TB vaccines, like public health impact and cost-effective modeling, and how modeling can be used to support TB vaccine advocacy efforts.
  • A Deadly Divide: TB Commitments vs TB Realities. Developed by the Stop TB Partnership Communities, Developing Country NGO, and Developed Country NGO Delegations to the Board with input from more than 1,000 civil society and affected community partners from 92 countries, this report analyzes progress against a series of commitments made by world leaders at the United Nations High-Level Meeting on TB (UNHLM) in 2018 and lays out priorities and six calls to action that are required to end the TB epidemic.
  • Video - Phumeza Tisile talk about her challenges in facing extensively drug-resistant TB, her vision of a TB free world, and how we can achieve it with new TB vaccines.
  • Member States must commit to invest in TB vaccine R&Dpublished by TB Vax ARM, is a one page document with information on the public health rationale for why Member States must commit to substantially increasing adequate, predictable, and sustainable financing for TB vaccine research at the UN High-Level Meeting on TB.
  • Recording: Prioritizing TB R&D at the UNLHM on TB and Beyond. Representatives from Global Health Advocates, RESULTS UK, RESULTS Canada, the the TB Vax ARM to present on recent TB R&D advocacy activities ahead of the HLM.
  • New Fair Share Targets for TB Research: 0.1% -> 0.15%. In 2017, Treatment Action Group (TAG) and partners introduced the 'fair share' funding targets for TB research calling for each country to spend at least 0.1% of its overall research and development (R&D) expenditures on TB R&D in order to meet global TB research funding goals. In August, TAG released an updated Information note providing details on the new 0.15% fair share funding targets for TB research, and the methodology and sources of data behind them.
  • Ready Next Time is a report by Campaigns in Global Health that maps the intersection between efforts to strengthen pandemic prevention, preparedness and response (PPPR) systems and efforts to end TB. It sets out how policymakers and funders can deliver impact across both agendas, saving lives today and tomorrow and helping to make the case for sustained investment in public health.

Contact us if you have resources related to advocacy, policy, and funding for TB vaccine R&D that you would like to share.

Resources for Community Engagement

Contact us if you have community engagement resources and materials that you would like to share.

Recent Scientific Publications

March 2024 Publications

Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D